|
No. of tumor samples (AZTS)
|
28
|
34
|
|
No. of tumor samples (all datasets)
|
944
|
762
|
|
EMT expression signature
|
mesenchymal
|
epithelial
|
|
Survival prognosis
|
poor
|
good
|
|
Microsatellite status
|
similar number of MSI and MSS CRC
|
enriched with MSS CRC
|
|
iNMF step 2
|
|
Molecular feature
|
Subtype 1.1
|
Subtype 1.2
|
Subtype 1.3
|
Subtype 2.1
|
Subtype 2.2
|
|
No. of tumor samples (AZTS)
|
12
|
9
|
7
|
14
|
20
|
|
No. of tumor samples (all datasets)
|
313
|
303
|
328
|
313
|
449
|
|
Average percent tumor foci area
|
79.2
|
81.4
|
77.9
|
82.1
|
79.7
|
|
Average percent tumor cells in foci
|
76.3
|
74.5
|
80.0
|
73,8
|
73.7
|
|
Average percent stromal cells in foci
|
18.3
|
18.3
|
12.2
|
21.2
|
21.2
|
|
Average percent inflammatory cells in foci
|
3.8
|
7.2
|
6.4
|
3.5
|
4.7
|
|
EMT expression signature
|
strongly mesenchymal
|
mesenchymal
|
mesenchymal
|
epithelial
|
epithelial
|
|
Tumor location colon/left/rectum/right
|
0/26/16/15
|
1/12/1/29
|
0/12/2/11
|
1/22/9/37
|
1/50/11/33
|
|
Microsatellite status MSI/MSS
|
14/15
|
42/9
|
2/35
|
27/31
|
4/50
|
|
Tumor stage
|
enriched in late stage CRC
| | | | |
|
Gender enrichment Female/Male/Unknown
|
87/99/0
|
89/57/0
|
90/124/1
|
58/34/0
|
108/113/0
|
|
Up-regulated genes
|
Ca-signaling and SRF-targeted
|
immune system-related
|
transporters
|
stress response and immune system-related
|
cell cycle and amino acid synthesis; genes on 13q13, 13q14, 13q32-34 and 20q11and 20q13
|
